An observational study in CKD and Chronic Kidney Disease (Stages 3b-5), sponsored by Singapore Institute of Technology. Recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Singapore Institute of Technology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Renal Insufficiency, Chronic with a site in Singapore — 5 open to participants now, 9 under way, 5 of them phase 3. Renal Insufficiency, Chronic · Singapore.
Among the 32 studies in Renal Insufficiency, Chronic with a site in Singapore, this one is the only one that started in 2026, is one of 6 observational ones, and was the 32nd registered.
3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →5 of the 32 studies in Renal Insufficiency, Chronic with a site in Singapore are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Singapore, United States, Argentina and 39 more countries
Ages 18+
Alexandra Hospital · Sites in Singapore
Ages 21+
Novartis Pharmaceuticals · Sites in Singapore, United States, Argentina and 33 more countries
Ages 18–100
Amgen · Sites in Singapore, United States, Argentina and 7 more countries
Ages 0–18
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 15 · Phase 4 1
First in 2003; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 540 across the 25 interventional studies, 500 across the 6 observational. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 32 have an industry lead sponsor. The 10 most frequent:
Singapore Institute of Technology is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Singapore Institute of Technology has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Renal Insufficiency, Chronic with a site in Singapore that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT07804316Singapore Institute of TechnologyFostering Self-Empowerment in CKD Patients Through Food Choice Mapping | 2027-01-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Renal Insufficiency, Chronic with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project aims to develop mapping of food choices available for chronic kidney disease (CKD) patients when dining out in Singapore. Following the mapping, a mobile application will be developed based on renal dining out food map mobile application (RENDOFOMAP) and trialed on patients with CKD. The specific aims of the project include:
Participants with CKD will use the newly developed mobile application to find out if there is improvement in self-empowerment, quality of life, nutritional status, and serum biochemistry.
Diet is integral in CKD management; however, it is not sustainable for patients in the long term if there is solely emphasis on food restrictions without providing knowledge on modifying food choices to allow enjoyment. Thus, a strategic nutritional education approach needs to be adopted to maximise cost-effectiveness.
Patients' self-empowerment is gaining recognition as a means to optimise hospital resource utilisation, reduce healthcare costs, and decrease patients' dependency on medical services. This is particularly relevant for patients with chronic kidney disease (CKD), who are required to adhere to a disease management regimen that often conflicts with their pre-diagnosis lives and priorities.
In recent years, mobile applications have emerged as a popular platform for delivering nutrition education programs. Research indicates that mobile applications designed to engage patients and promote self-management of CKD show promise in improving adherence to dietary restrictions related to sodium, potassium, phosphorus, protein, calories, and fluid intake. Some of these applications offer a range of features but will still need to be reviewed by dietitians during face-to-face consultations. This in-depth approach, while beneficial, may not fully optimise time efficiency for dietitians.
Thus, there is an impetus to create an improved mobile application for CKD nutritional management to allow patients to individualise food choices, on top of charting food intake in the form of food diary. Patients can be trained to use the application during dietetics session which can eventually help reduce time spent for each session thereby improving dietitians' workload.
The proposed application will also incorporate some preliminary Artificial Intelligence (AI) to offer personalised food choices for patients. This feature is expected to further enhance the user-friendliness and convenience of the application, thereby promoting its usage and empowerment among CKD patients.
Participants will be recruited from inpatient and outpatient setting in a tertiary hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant will be provided access to the prototype mobile application known for this trial. Participants will be required to utilise the mobile application for 12 days (two 6-consecutive days, twice within 3 months) during a 3-month period. During the agreed dates, participant will need to take photos of their food intake and upload them onto the mobile application for evaluation.
Physical Health-Related Quality of Life
Physical Health-Related Quality of Life At baseline and Week 12-16, physical health-related quality of life will be assessed using the 12-Item Short Form Health Survey (SF-12). The Physical Component Summary (PCS) score ranges from 5 to 20, with lower scores indicating better health-related quality of life and higher scores indicating poorer health-related quality of life.
Time frame: Baseline to the end of study at 12-16 weeks
Mental Health-Related Quality of Life
At baseline and Week 12-16, mental health-related quality of life will be assessed using the 12-Item Short Form Health Survey (SF-12). The Mental Component Summary (MCS) score ranges from 12 to 45, with lower scores indicating better health-related quality of life and higher scores indicating poorer health-related quality of life.
Time frame: Baseline to the end of study at 12-16 weeks
Modified Nutrition-related Empowerment Scale
At baseline and Week 12-16, nutrition-related empowerment will be assessed using a modified version of the Korean Health Empowerment Scale (K-HES). The scale consists of 8 items scored from 1 (Strongly Disagree) to 5 (Strongly Agree). Item scores are summed to generate a total score ranging from 8 to 40, with higher scores indicating greater nutrition-related empowerment and self-management capacity.
Time frame: Baseline to the end of study at 12-16 weeks
Ease of Adherence to Diet Plan When Eating Out
Participants will rate the ease of adhering to their prescribed diet plan when eating out using a 5-point scale ranging from 1 (very difficult) to 5 (very easy). Higher scores indicate greater ease of dietary adherence.
Time frame: Baseline to the end of study at 12-16 weeks
Food Diary Completion Rate
Participant engagement with the nEAT mobile application will be assessed by the proportion of scheduled food diary entries completed during the intervention period. Food diary completion rate (%) = (Number of completed food diary entries ÷ Total number of scheduled food diary entries) × 100. A food diary entry is considered completed when the participant records the required dietary information for the scheduled eating occasion within the nEAT mobile application
Time frame: Baseline to the end of study at 12-16 weeks
Body Weight Change
Body weight will be measured at baseline and Week 12-16 using a calibrated weighing scale. Weight will be reported in kilograms (kg). Body weight change (kg) = Body weight at Week 12-16 - Body weight at baseline. Negative values indicate a reduction in body weight (weight loss), positive values indicate an increase in body weight (weight gain), and a value of 0 indicates no change in body weight.
Time frame: Baseline to the end of study at 12-16 weeks
Percentage Weight Change
Percentage weight change over the preceding 6 months will be calculated from self-reported and/or documented body weight records. Weight change will be reported as a percentage (%).
Time frame: Baseline to the end of study at 12-16 weeks
Body Mass Index (BMI)
Body mass index (BMI) will be calculated as weight (kg) divided by height squared (m²), expressed as kg/m². BMI Asian categories are Underweight: Less than 18.5 kg/m² Normal range: 18.5 to 22.9 kg/m² Overweight (At risk): 23.0 to 24.9 kg/m² Obese (Class I): 25.0 to 29.9 kg/m² Obese (Class II): ≥ 30.0 kg/m²
Time frame: Baseline to the end of study at 12-16 weeks
Nutritional Status [Subjective Global Assessment (SGA)}
Nutritional status will be assessed using the Subjective Global Assessment (SGA), incorporating recent weight loss, dietary intake, gastrointestinal symptoms, functional status, muscle wasting, fat wasting, oedema, and overall nutritional status. Overall subjective scores range from 1 to 7, where 1-2 indicates severely malnourished, 3-5 moderately malnourished and 6-7 indicates being well nourished.
Time frame: Baseline to the end of study at 12-16 weeks
Ease of Adherence to Diet Plan When Eating at Home
Participants will rate the ease of adhering to their prescribed diet plan when eating at home before and after using nEAT mobile application using a 5-point scale ranging from 1 (very difficult) to 5 (very easy). Higher scores indicate greater ease of dietary adherence.
Time frame: Baseline to the end of study at 12-16 weeks
Energy Intake Relative to Estimated Requirements
Energy intake will be assessed using 24-hour dietary recalls completed at baseline and end of study at 12-16 weeks. Individual energy requirements will be estimated using the Harris-Benedict equation based on age (years), weight (kg), and height (cm), and used to establish personalized energy targets. Energy intake will be expressed as a percentage of the estimated energy requirement (%), calculated as actual energy intake divided by estimated energy requirement × 100. Values closer to 100% indicate greater adherence to prescribed energy targets.
Time frame: Baseline to the end of study at 12-16 weeks
Protein Intake Relative to Estimated Requirements
Protein intake will be assessed using 24-hour dietary recalls completed at baseline and end of study at 12-16 weeks. Individual actual protein requirements will be estimated using the factor 0.8g/kg x weight (kg), and used to establish personalized energy targets. Protein intake will be expressed as a percentage of the estimated protein requirement (%), calculated as actual protein intake divided by estimated protein requirement × 100. Values closer to 100% indicate greater adherence to prescribed energy targets.
Time frame: Baseline to the end of study at 12-16 weeks
Sodium Intake Relative to Estimated Requirements
Sodium intake will be assessed using 24-hour dietary recalls completed at baseline and end of study at 12-16 weeks. Individual sodium allowance will limited to 2000mg per person . Energy intake will be expressed as a percentage of the sodium allowance (%), calculated as actual sodium intake divided by estimated sodium allowance × 100. Values closer to 100% indicate greater adherence to prescribed sodium targets.
Time frame: Baseline to the end of study at 12-16 weeks
Phosphorus Intake Relative to Estimated Requirements
Phosphorus intake will be assessed using 24-hour dietary recalls completed at baseline and end of study at 12-16 weeks. Individual phosphorus allowances will be personalised and estimated proportionally to protein intake. Phosphorus intake will be expressed as a percentage of the estimated phosphorus allowance (%), calculated as actual phosphorus intake divided by estimated phosphorus allowance × 100. Values closer to 100% indicate greater adherence to prescribed phosphorus targets.
Time frame: Baseline to the end of study at 12-16 weeks
Potassium Intake Relative to Estimated Requirements
Potassium intake will be assessed using 24-hour dietary recalls completed at baseline and end of study at 12-16 weeks. Individual potassium allowance will calculated at 39mg/kg per person, however, will be personalised based on the chronic kidney stage and serum biochemistry potassium. Potassium intake will be expressed as a percentage of the individualised potassium allowance (%), calculated as actual sodium intake divided by estimated potassium allowance × 100. Values closer to 100% indicate greater adherence to prescribed potassium targets.
Time frame: Baseline to the end of study at 12-16 weeks
Change in Estimated Glomerular Filtration Rate (eGFR)
Estimated glomerular filtration rate (eGFR), a laboratory-based measure of kidney function, will be assessed at baseline and at the end of the study (12-16 weeks). eGFR will be reported in millilitres per minute per 1.73 m² (mL/min/1.73 m²). The outcome measure will be the change in eGFR from baseline to study completion. Lower eGFR values compared to baseline indicate poorer kidney function.
Time frame: Baseline to the end of study at 12-16 weeks
Change in Serum Creatinine
Renal function will be assessed by measuring serum creatinine concentration and reported in micromoles per litre (µmol/L) at baseline and end of study at 12-16 weeks. Higher values from baseline indicate poorer or declining kidney function. Reference value, male: 54 - 101; female: 37 - 75 µmol/L
Time frame: Baseline to the end of study at 12-16 weeks
Serum Potassium Concentration
Serum potassium concentration will be measured and reported in millimoles per litre (mmol/L). Reference value: 3.6 - 5.0 mmol/L. Higher value from baseline signifies worsening of hyperkalemia
Time frame: Baseline to the end of study at 12-16 weeks
Change in Serum Albumin
Nutritional status will be assessed using serum albumin concentration and reported in grams per litre (g/L) at baseline and end of study at 12-16 weeks. Higher values indicate better nutritional status compared to baseline. Reference value: 40 - 51 g/L
Time frame: Baseline to the end of study at 12-16 weeks
CKD-Related Hospital Admissions Compared Against Compliance to 24-hour Diet Recall
Hospital admissions related to chronic kidney disease or its complications occurring during the study period will be recorded and reported as the total number of admissions in comparison to the stratification of24-hour Diet Recall.
Time frame: End of study at 12-16 weeks
Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Singapore Institute of Technology